Human Peripheral Blood Leukopaks® provide an enriched peripheral blood mononuclear cell (PBMC) fraction with low granulocytes and red blood cells as compared to buffy coats obtained from density gradient centrifugation of whole blood. This highly enriched PBMC fraction requires minimal downstream processing (i.e. Ficoll, RBC lysis, etc.) and can be used directly for isolating high-yields of immune cells, such as CD4+ T cells, CD8+ T cells, CD19+ B cells, monocytes, and a variety of other immune cells and subsets. This allows researchers greater reproducibility of experiments from a single donor (minimizing donor-to-donor variation), scalability of experiments from a single cell type, and a decrease in same cell variability. Additionally, 200-300mL of plasma can be collected at the time of the donor draw. Up to 12 Leukopak collections can be performed on the same donor in a given year, providing an ample amount of PBMCs for large-scale experiments and research studies.
• Enriched PBMCs
• 0.1-0.2% CD34+ cells
• Low hematocrit
• Low granulocytes
Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols.
We work closely with our customers to provide them with the product they need. For a custom order, please call and speak to one of our sales specialists at 530-303-3828.
|Cell and Tissue Source||Peripheral Blood|
|Cell Type||Mononuclear Cells|
|Donor Attributes||HIV-, HepB-, HepC-|
|Viability||≥90% by Flow Cytometry|
Product Information Sheet
Certificate of Analysis
Material Safety Data Sheet
Figure 1. Representative flow analysis of a peripheral blood Leukopak after RBC lysis.